Pharmacologic management of atrial fibrillation

Journal of Cardiovascular Electrophysiology

Volumn 8, Issue 7, 1997, Pages 818-829

  Riley, Reed D ^b   Pritchett, Edward L C ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b SINAI HOSPITAL OF BALTIMORE   (United States)

Author keywords

Antiarrhythmic drugs; Defibrillation; Stroke; Thromboembolism

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DILTIAZEM; DISOPYRAMIDE; FLECAINIDE; LOCAL ANESTHETIC AGENT; PROCAINAMIDE; PROPAFENONE; SOTALOL; WARFARIN;

ANTIARRHYTHMIC ACTIVITY; ANTICOAGULATION; ARTICLE; CLINICAL TRIAL; DEFIBRILLATION; DRUG EFFICACY; HEART ATRIUM FIBRILLATION; HEART ATRIUM PACEMAKER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RISK MANAGEMENT; STROKE; THROMBOEMBOLISM; TREATMENT INDICATION;

EID: 0030856934     PISSN: 10453873     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1540-8167.1997.tb00841.x     Document Type: Article

References (95)

1. Lewis RV, Irvine N, McDevitt DG: Relationships between heart rate, exercise tolerance and cardiac output in atrial fibrillation: The effects of treatment with digoxin, verapamil and diltiazem. Eur Heart J 1988;9: 777-781.
2. Rawles JM: What is meant by a "controlled" ventricular rate in atrial fibrillation? Br Heart J 1990;63:157-161.
3. Atrial Fibrillation Investigators: Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994;154: 1449-1457.
4. Cabin HS, Clubb KS, Hall C, et al: Risk for systemic embolization of atrial fibrillation without mitral stenosis. Am J Cardiol 1990;65:1112-1116.
5. Wolf PA, Abbott RD, Kannel WB: Atrial fibrillation: A major contributor to stroke in the elderly. The Framingham Study. Arch Intern Med 1987;147:1561-1564.
6. Wolf PA, Dawber TA, Thomas EH Jr, et al Epidemiologie assessment of chronic atrial fibrillation and risk of stroke: The Framingham Study. Neurology 1978; 28:973-977.
7. Gajewski J, Singer RB: Mortality in an insured population with atrial fibrillation. JAMA 1981;245:1540-1544.
8. Kannel WB, Abbott RD, Savage DD, et al: Epidemiologic features of chronic atrial fibrillation. The Framingham Study. N Engl J Med 1982;306:1018-1022.
9. Bialy D, Lehmann MH, Schumacher DN, et al: Hospitalization for arrhythmias in the United States: Importance of atrial fibrillation. (Abstract) J Am Coll Cardiol 1992;19:41A.
10. Wolf PA, Abbott RD, Kannel WB: Atrial Fibrillation as an independent risk factor for stroke: The Framingham Study. Stroke 1991;22:983-987.
11. Kannel WB, Abbott RD, Savage DD, et al: Coronary heart disease and atrial fibrillation: The Framingham Study. Am Heart J 1983;106:389-396.
12. Ostrander LD Jr, Brandt R, Kjelsberg M, et al: Electrocardiographic findings among the adult population of a total natural community, Tecumseh, Michigan. Circulation 1965;31:888-898.
13. Cameron A, Schwartz MJ, Kronmal RA, et al: Prevalence and significance of atrial fibrillation in coronary artery disease (CASS Registry). Am J Cardiol 1988; 61:714-717.
14. Gold H, Kwit NT, Otto H, et al: Physiological adaptations in cardiac slowing by digitalis and their bearing on problems of digitalization in patients with auricular fibrillation. J Pharmacol Exp Ther 1939;67: 224-238.
15. Goodman DJ, Rossen RM, Cannom DS, et al: Effect of digoxin on atrioventricular conduction: Studies on patients with and without cardiac autonomie innervation. Circulation 1975;51:251-256.
16. Falk RH, Leavitt JI: Digoxin for atrial fibrillation: A drug whose time has gone? Ann Intern Med 1991; 114:573-575.
17. Beasley R, Smith DA, McHaffie DJ: Exercise heart rates at different serum digoxin concentrations in patients with atrial fibrillation. Br Med J 1985;290:9-11.
18. Masuhara JE, Lalonde RL: Serum digoxin concentrations in atrial fibrillation: A review. Drug Intelligence Clin Pharm 1982;16:543-546.
19. Klein HO, Kaplinsky E: Verapamil and digoxin: Their respective effects on atrial fibrillation and their interaction. Am J Cardiol 1982;50:894-902.
20. Mungall DR, Robichaux RP, Perry W, et al: Effects of quinidine on serum digoxin concentration: A prospective study. Ann Intern Med 1980;93:689-693.
21. Belz G, Doering W, Munkes R, et al: Interaction between digoxin and calcium antagonists and antiarrhythmic drugs. Clin Pharmacol Ther 1983;33:410-417.
22. Moorman JR, Pritchett EC: The arrhythmias of digitalis intoxication. Arch Intern Med 1985;145:1289-1292.
23. Redfors A: Digoxin dosage and ventricular rate at rest and exercise in patients with atrial fibrillation. Acta Med Scand 1971;190:321-333.
24. The Esmolol vs Placebo Multicenter Study Group: Comparison of the efficacy and safety of esmolol, a short-acting beta blocker, with placebo in the treatment of supraventricular tachyarrhythmias. Am Heart J 1986;111:42-48.
25. David D, Segni ED, Klein HO, et al: Inefficacy of digitalis in the control of heart rate in patients with chronic atrial fibrillation: Beneficial effect of an added beta-adrenergic blocking agent. Am J Cardiol 1979;44:1378.
26. Goldman S, Probst P, Selzer A, et al: Inefficacy of "therapeutic" serum levels of digoxin in controlling the ventricular rate in atrial fibrillation. Am J Cardiol 1975;35:651-655.
27. Anderson JL, Gilbert EM, Alpert BL, et al., and the Flecainide Supraventricular Tachycardia Study Group: Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy. A multicenter, double-blind, crossover study of flecainide and placebo with transtelephonic monitoring. Circulation 1989;80: 1557-1570.
28. Rawles JM, Metcalfe MJ, Jennings K: Time of occurrence, duration, and ventricular rate of paroxysmal atrial fibrillation: The effect of digoxin. Br Heart J 1990;63:225-227.
29. Gakin E, Flugelman M, Glickson M, et al: Failure of long-term digitalization to prevent rapid ventricular response in patients with paroxysmal atrial fibrillation. Chest 1991;99:1038-1040.
30. Zipes D, Fischer J: Effects of agents which inhibit the slow channel on sinus node automaticity and atrioventricular conduction in the dog. Circ Res 1974;34:184-192.
31. Wit A, Cranefield P: Effect of verapamil on the sinoatrial and atrioventricular nodes of the rabbit and the mechanism by which it arrests reentrant atrioventricular nodal tachycardia. Circ Res 1974;35:413-425.
32. Schwartz JB, Keefe D, Kates RE, et al: Acute and chronic pharmacodynamic interaction of verapamil and digoxin in atrial fibrillation. Circulation 1982;65: 1163-1170.
33. Stern E, Pitchon R, King B, et al: Clinical use of oral verapamil in chronic and paroxysmal atrial fibrillation. Chest 1982;81:308-311.
34. Lang R, Klein H, Weiss E, et al: Superiority of oral verapamil therapy to digoxin in treatment of chronic atrial fibrillation. Chest 1983;83:491-499.
35. Hwang MH, Danoviz J, Pacold I, et al: Double-blind crossover randomized trial of intravenously administered verapamil. Its use for atrial fibrillation and flutter following open heart surgery. Arch Intern Med 1984;144:491-494.
36. Ellenbogen K, Dias V, Plumb V, et al: A placebo-controlled trial of continuous intravenous diltiazem infusion for 24-hour heart rate control during atrial fibrillation and atrial flutter: A multicenter study. J Am Coll Cardiol 1991;18:891-897.
37. Steinberg JS, Katz RJ, Bren GB, et al: Efficacy of oral diltiazem to control ventricular response in chronic atrial fibrillation at rest and during exercise. J Am Coll Cardiol 1987;9:405-411.
38. Atwood JE, Myers JN, Sullivan MJ, et al: Diltiazem and exercise performance in patients with chronic atrial fibrillation. Chest 1988;92:20-25.
39. Bohm M, Schwinger RG, Erdmann E: Different cardiodepressant potency of various calcium antagonists in human myocardium. Am J Cardiol 1990;65:1039-1041.
40. Heywood JT, Graham B, Murais G, et al: Effects of intravenous diltiazem on rapid atrial fibrillation accompanied by congestive heart failure. Am J Cardiol 1991;67:1150-1152.
41. Anderson S, Blanski L, Byrd RC, et al., The Esmolol vs Placebo Multicenter Study Group: Comparison of the efficacy and safety of esmolol, a short-acting beta blocker, with placebo in the treatment of supraventricular tachyarrhythmias. Am Heart J 1986;111:42-48.
42. DiBianco R, Morganroth J, Freitag JA, et al: Effects of nadolol on the spontaneous and exercise-provoked heart rate of patients with chronic atrial fibrillation receiving stable dosages of digoxin. Am Heart J 1984; 108:1121-1127.
43. Atwood JE, Sullivan M, Forbes S, et al: Effect of beta-adrenergic blockade on exercise performance in patients with chronic atrial fibrillation. J Am Coll Cardiol 1987;10:314-320.
44. Wong C, Lau C, Leung W, et al: Usefulness of labetalol in chronic atrial fibrillation. Am J Cardiol 1990;66:1212-1215.
45. Petersen P, Madsen EB, Brun B, et al: Silent cerebral infarction in chronic atrial fibrillation. Stroke 1987; 18:1098-1100.
46. Stroke Prevention in Atrial Fibrillation Investigators: Predictors of thromboembolism in atrial fibrillation: II. Echocardiographic features of patients at risk. Ann Intern Med 1992;116:6-12.
47. Stroke Prevention in Atrial Fibrillation Investigators: Predictors of thromboembolism in atrial fibrillation: I. Clinical features of patients at risk. Ann Intern Med 1992;116:1-5.
48. Cosgriff S: Prophylaxis of recurrent embolism of intracardiac origin. JAMA 1950;143:870-872.
49. Daly R, Mattingly TW, Holt CL: Systemic arterial embolism in rheumatic heart disease. Am Heart J 1951;42:566-581.
50. Hirsh J: Oral anticoagulant drugs. N Engl J Med 1991;324:1865-1875.
51. Stroke Prevention in Atrial Fibrillation Investigators: Warfarin versus aspirin Cor prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994;343:687-691.
52. Stroke Prevention in Atrial Fibrillation Investigators: Stroke Prevention in Atrial Fibrillation Study: Final results. Circulation 1991;84:527-539.
53. Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators: Effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 1990;323:1505-1511.
54. Petersen P, Boysen G, Godtfredsen J, et al: Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK Study. Lancet 1989;1:175-179.
55. Connolly SJ, Laupacis A, Gent M, et al: Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol 1991;18:349-355.
56. Ezekowitz MD, Bridgers SL, James KE, et al: Warfarin in the prevention of stroke associated with non-rheumatic atrial fibrillation. N Engl J Med 1992;327: 1406-1412.
57. EAFT (European Atrial Fibrillation Trial) Study Group: Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemie attack or minor stroke. Lancet 1993;342:1255-1262.
58. Brand FN, Abbott RD, Kannel WB, et al: Characteristics and prognosis of lone atrial fibrillation, 30-year follow-up in the Framingham Study. JAMA 1985; 254:3449-3453.
59. Kopecky SL, Gersh BJ, McGoon MD, et al: The natural history of lone atrial fibrillation. A population-based study over three decades. N Engl J Med 1987; 317:669-674.
60. Morris JJ, Entman M, North WC, et al: The changes in cardiac output with reversion of atrial fibrillation in sinus rhythm. Circulation 1965;31:670-678.
61. Atwood JE, Myers J, Sullivan M, et al: The effect of cardioversion on maximal exercise capacity in patients with chronic atrial fibrillation. Am Heart J 1989;118:913-918.
62. Lipkin DP, Frenneaux M, Stewart R, et al: Delayed improvement in exercise capacity after cardioversion of atrial fibrillation to sinus rhythm. Br Heart J 1988; 59:572-577.
63. Szekely P, Sideris D, Batson G: Maintenance of sinus rhythm after atrial fibrillation. Br Heart J 1970;32: 741-746.
64. Suttorp M, Kingma JH, Koomen E, et al: Recurrence of paroxysmal atrial fibrillation or flutter after successful cardioversion in patients with normal left ventricular function. Am J Cardiol 1993;71:710-713.
65. Dittrich HC, Erickson JS, Schneiderman T, et al: Echocardiographic and clinical predictors for outcome of elective cardioversion of atrial fibrillation. Am J Cardiol 1989;63:193-197.
66. Ewy GA, Ulfers L, Hager WD, et al: Response of atrial fibrillation to therapy: Role of etiology and left atrial diameter. J Electrocardiol 1980;13:119-124.
67. Henry WL, Morganroth J, Pearlman AS, et al: Relation between echocardiographically determined left atrial size and atrial fibrillation. Circulation 1976;53: 273-279.
68. Bjerkelund CJ, Orning OM: The efficacy of anticoagulant therapy in preventing embolism related to D.C. electrical conversion of atrial fibrillation. Am J Cardiol 1969;23:208-216.
69. Manning WJ, Silverman DI, Keighley CS, et al: Transesophageal echocardiographically facilitated early cardioversion from atrial fibrillation using short-term anticoagulation: Final results of a prospective 4.5-year study. J Am Coll Cardiol 1995;6:1354-1361.
70. Lown B, Amarasingham R, Neuman J: New method for terminating cardiac arrhythmias. JAMA 1962;182: 548-555.
71. Lundstrom T, Ryden L: Chronic atrial fibrillation. Long-term results of direct current conversion. Acta Med Scand 1988;223:53-59.
72. Hohnloser SH, van de Loo A, Baedeker F: Efficacy and proarrhythmic hazards of pharmacologie cardioversion of atrial fibrillation: Prospective comparison of sotalol versus quinidine. J Am Coll Cardiol 1995;26:852-858.
73. Halpern SW, Ellrodt G, Singh BN, et al: Efficacy of intravenous procainamide infusion in converting atrial fibrillation to sinus rhythm. Relation to left atrial size. Br Heart J 1980;44:589-595.
74. Connolly S, Mulji A, Hoffen D, et al: Randomized placebo-controlled trial of propafenone for treatment of atrial tachyarrhythmias after cardiac surgery. J Am Coll Cardiol 1987;10:1145-1148.
75. Campbell T, Gavughan T, Morgan J: Intravenous sotalol for the treatment of atrial fibrillation and flutter after cardiopulmonary bypass: Comparison with disopyramide and digoxin in a randomised trial. Br Heart J 1985;54:86-90.
76. Borgeat A, Goy J, Maendly R, et al: Flecainide versus quinidine for conversion of atrial fibrillation to sinus rhythm. Am J Cardiol 1986;58:496-498.
77. Brodsky M, Allen B, Walker CI, et al: Amiodarone for maintenance of sinus rhythm after conversion of atrial fibrillation in the setting of a dilated left atrium. Am J Cardiol 1987;60:572-575.
78. Kopelman H, Horowitz L: Efficacy and toxicity of amiodarone for the treatment of supraventricular tachyarrhythmias. Prog Cardiovasc Dis 1989;31:355-366.
79. Anonymous: Ibutilide. Med Lett Drugs Therap 1996; 38:38.
80. Coplen SE, Antmann EM, Berlin JA, et al: Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials. Circulation 1990;82:1106-1116.
81. Karlson BW, Torstensson I, Abjorn C, et al: et al: Disopyramide in the maintenance of sinus rhythm after electroconversion of atrial fibrillation. A placebo-controlled one-year follow-up study. Eur Heart J 1988;9:284-290.
82. van Gelder IC, Crijns HJGM, Van Gilst WH, et al: Efficacy and safety of flecainide acetate in the maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation or atrial flutter. Am J Cardiol 1989;64:1317-1321.
83. Connolly SJ, Hoffert DL: Usefulness of propafenone for recurrent paroxysmal atrial fibrillation. Am J Cardiol 1989;63:817-819.
84. Van Wijk LM, den Heijer P, Crijns HJ, et al: Flecainide versus quinidine in the prevention of paroxysms of atrial fibrillation. J Cardiovasc Pharmacol 1989;13:32-36.
85. Anonymous: The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989;32:406-412.
86. Pritchett ELC, McCarthy EA, Wilkinson WE: Propafenone treatment of symptomatic paroxysmal supraventricular arrhythmias. A randomized, placebo-controlled, cross-over trial in patients tolerating oral therapy. Ann Intern Med 1991;114:539-544.
87. Madden JL: Resection of the left auricular appendix: A prophylaxis for recurrent arterial emboli. JAMA 1949;140:769.
88. Cox JL: The surgical treatment of atrial fibrillation. IV. Surgical technique. J Thorac Cardiovasc Surg 1991;101:584-592.
89. Cox JL, Boineau JP, Schuessler RB, et al: Five-year experience with the Maze procedure for atrial fibrillation. Ann Thorac Surg 1993;56:814-823.
90. Cox JL, Boineau JP, Schuessler RB, et al: Electrophysiologic basis, surgical development, and clinical results of the Maze procedure for atrial flutter and atrial fibrillation. Adv Card Surg 1995;6:1-67.
91. Haissaguerre M, Gencel L, LeMetayer P, et al: Successful catheter ablation of atrial fibrillation. J Cardiovasc Electrophysiol 1994;5:1045-1052.
92. Gallagher JJ, Svenson RH, Kasell JH, et al: Catheter technique for closed-chest ablation of the atrioventricular conduction system. N Engl J Med 1982;306:194-200.
93. Langberg JJ, Chin MC, Rosenqvist M, et al: Catheter ablation of the atrioventricular junction with radiofrequency energy. Circulation 1989;80:1527-1535.
94. Williamson BD, Man KC, Daoud E, et al: Radiofrequency catheter modification of atrioventricular conduction to control the ventricular rate during atrial fibrillation [see comments] [published erratum appears in N Engl J Med 1995;332:479]. N Engl J Med 1994;331:910-917.
95. Page RL, Wilkinson WE, Clair WK, et al: Asymptomatic arrhythmias in patients with symptomatic paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia. Circulation 1994;89:224-227.